MolecuLight's Breakthrough Imaging Technology Promotes Health Equity in Wound Care

MolecuLight Inc. Ontario Pennsylvania

is a privately owned medical imaging company with a global presence that manufactures and commercializes the MolecuLight i:X® and DX™ wound imaging devices. These are the only class II FDA-cleared point-of-care imaging devices for the real-time detection of elevated bacterial burden in wounds. They also provide accurate digital wound measurement for comprehensive wound management, supported by strong clinical evidence including over 100 peer-reviewed publications.

____________________________
i U.S. Department of Health and Human Services Office of Minority Health, "Diabetes and African Americans" [Accessed June 27, 2024] Available from: https://minorityhealth.hhs.gov/diabetes-and-african-americans

ii Brennan MB, Powell WR, Kaiksow F, et al. Association of Race, Ethnicity, and Rurality With Major Leg Amputation or Death Among Medicare Beneficiaries Hospitalized With Diabetic Foot Ulcers. JAMA Netw Open. 2022;5(4):e228399.

For sales, media or other inquiries or further information, please contact: Hunter Zudans , Director of Marketing, MolecuLight Corp., T. +1.484.682.7580, [e-mail], www.moleculight.com

Photo - https://mma.prnewswire.com/media/2480199/MolecuLight_MolecuLight_s_Breakthrough_Imaging_Technology_Promot.jpg

View original content:https://www.prnewswire.co.uk/news-releases/moleculights-breakthrough-imaging-technology-promotes-health-equity-in-wound-care-302220780.html